Ranbaxy Outperforms Behind Generic Valtrex, But FDA Corrective Action Looms
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Ranbaxy Laboratories, now a subsidiary of Japanese Daiichi Sankyo, has posted better than expected first quarter results and has many positive developments to look forward to, but analysts remain cautious about potential U.S. FDA action and turnaround time of generic opportunities in Japan